Operating Segments (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2017	Jun. 30, 2016	Dec. 31, 2016
Summary of segmental information
Contract Revenue	$ 990,971	$ 3,160,050	$ 2,321,855	$ 5,791,037
Income (Loss) from Operations	(2,316,829)	(1,009,958)	(4,055,019)	(2,915,663)
Amortization and Depreciation Expense	18,621	22,828	39,671	45,436
Other Income (Expense), Net	5,231	917,183	9,984	1,673,455
Share-Based Compensation	94,047	200,273	240,674	336,684
Identifiable Assets	6,773,622		6,773,622		$ 10,267,105
Vaccines/BioDefense [Member]
Summary of segmental information
Contract Revenue	990,971	3,160,050	2,321,855	5,791,037
Income (Loss) from Operations	197,270	734,120	333,870	1,052,111
Amortization and Depreciation Expense	9,611	10,041	19,380	20,060
Share-Based Compensation	14,973	24,223	32,971	52,229
Identifiable Assets	783,821		783,821		1,297,986
BioTherapeutics [Member]
Summary of segmental information
Contract Revenue
Income (Loss) from Operations	(1,574,261)	(668,260)	(2,601,816)	(1,914,682)
Amortization and Depreciation Expense	8,077	10,564	17,644	20,996
Share-Based Compensation	22,827	30,985	72,597	65,817
Identifiable Assets	37,320		37,320		49,422
Corporate [Member]
Summary of segmental information
Income (Loss) from Operations	(939,838)	(1,075,818)	(1,787,073)	(2,053,092)
Amortization and Depreciation Expense	933	2,223	2,647	4,380
Other Income (Expense), Net	5,231	917,183	9,984	1,673,455
Share-Based Compensation	56,247	$ 145,065	135,106	$ 218,638
Identifiable Assets	$ 5,952,481		$ 5,952,481		$ 8,919,698